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Introduction
Normal endothelial functions include control of platelet ad-
hesion, mediation of coagulation and immune function, and 
control of volume and electrolyte content of body compo-
nents.1) Endothelial dysfunction is a pathophysiological condi-
tion of abnormal process carried out by the endothelium. It is 
thought to be a key initial step in the development of athero-
sclerosis and can be used as a prognostic marker in predicting 
cardiovascular events including stroke and heart attacks.2)3) 
Endothelial dysfunction can be resulted from disease processes 
including hypertension, dyslipidemia, and diabetes as well as 
from environmental factors such as smoking.1)
Endothelial dysfunction can be characterized as the inability 
of arteries to dilate fully in response to appropriated stimuli. 
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Background: Smoking is one of well known environmental factors causing endothelial dysfunction and plays important role 
in the atherosclerosis. We investigated the effect of cilostazol could improve the endothelial dysfunction in smokers with the 
measurement of flow-mediated dilatation (FMD).
Methods: We enrolled 10 normal healthy male persons and 20 male smokers without any known cardiovascular diseases. After 
measurement of baseline FMD, the participants were medicated with oral cilostazol 100 mg bid for two weeks. We checked the 
follow up FMD after two weeks and compared these values between two groups.
Results: There was no statistical difference of baseline characteristics including age, body mass index, serum cholesterol 
profiles, serum glucose and high sensitive C-reactive protein between two groups. However, the control group showed significantly 
higher baseline endothelium-dependent dilatation (EDD) after reactive hyperemia (12.0 ± 4.5 % in the control group vs. 8.0 ± 
2.1% in the smoker group, p = 0.001). However, endothelium-independent dilatation (EID) after sublingual administration of 
nitroglycerin was similar between the two groups (13.6 ± 4.5% in the control group vs. 11.9 ± 4.9% in the smoker group, p = 
0.681). Two of the smoker group were dropped out due to severe headache. After two weeks of cilostazol therapy, follow-up EDD 
were significantly increased in two groups (12.0 ± 4.5% to 16.1 ± 3.7%, p = 0.034 in the control group and 8.0 ± 2.1% to 12.2 
± 5.1%, p = 0.003 in the smoker group, respectively). However, follow up EID value was not significantly increased compared 
with baseline value in both groups (13.6 ± 4.5% to 16.1 ± 3.7%, p = 0.182 in the control group and 11.9 ± 4.9% to 13.7 ± 
4.3%, p = 0.430 in the smoker group, respectively).
Conclusion: Oral cilostazol treatment significantly increased the vasodilatory response to reactive hyperemia in two groups. It 
can be used to improve endothelial function in the patients with endothelial dysfunction caused by cigarette smoking.
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This can be detected by flow-mediated dilatation (FMD) us-
ing temporary arterial occlusion by inflating a blood pressure 
cuff to high pressures.4) Flow-mediated changes in conduit ar-
tery diameter are caused by shear-stress induced generation of 
endothelia derived vasoactive mediators including nitric ox-
ides.5)6)
Cilostazol (Otsuka Pharmaceutical Co. Tokushima, Japan), 
6-[4-(1-cyclohexyl-1H-tetrazol-5-yl)butoxy]-3,4-dihydro-
2(1H)-quinolinone, is a 2-oxo-quinoline derivative with anti-
thrombotic, vasodilator, antimitogenic and cardiotonic proper-
ties.7) The compound is a potent inhibitor of phosphodiesterase 
(PDE)-3. It may be useful for treating chronic arterial occlu-
sive diseases and symptoms of intermittent claudication.8) Cilo-
stazol inhibits platelet aggregation and has considerable anti-
thrombotic effects in vivo. Also, this compound relaxes vascular 
smooth muscle and inhibits mitogenesis and migration of vas-
cular smooth muscle cells. In the heart, it has positive inotropic 
and chronotropic effects.7)8)
This present study investigated the effects of cilostazol that 
could improve the endothelial dysfunction, especially in young 
male smokers. 
Methods
Subjects
We enrolled 10 healthy male non-smokers and 20 active 
male smokers, average 6.0 ± 3.3 pack years, with matching 
age and weight. They were all volunteers without having a past 
or present history of coronary diseases and the results of clini-
cal laboratory tests showing no signs of hypertension, dyslip-
idemia or diabetes. They filled up the informed consent. Total 
200 mg/day of oral cilostazol was administered divided into 
morning and evening for two weeks. The levels of smoking in 
the smoker group were remained constantly during the study 
period.
Vascular endothelial function test
FMD was measured according to the methods of previously 
reported article by Celermajer et al.3) Each participants rested 
for about 20 minutes, and their internal diameter of the bra-
chial artery were measured with a Sequoia 512 (Siemens Med-
ical Solutions, Mountain View, CA) equipped with a 10-MHz 
linear ultrasound probe. 
The diameter of the brachial artery was measured in the re-
sponse to an increase in blood flow (causing shear-stress) dur-
ing reactive hyperemia (induced by transient inflation of a 
blood pressure cuff). This leads to endothelium-dependent 
dilatation (EDD). Endothelium-independent dilatation (EID) 
was defined as a proportional increase in the diameter to sub-
lingual nitroglycerin, an endothelium-independent dilator. The 
brachial artery was scanned and the diameter measured during 
four conditions; at baseline, during reactive hyperemia (in-
duced by transient inflation of a sphygmomanometer cuff), 20 
minutes after hyperemia and finally after administration of a 
sublingual nitroglycerin. After measurement of baseline bra-
chial artery diameter (BD0), a sphygmomanomter cuff was 
used to apply up to 200 mmHg of pressure for 5 minutes 
around the upper part of the arm. Follow-up brachial artery 
diameter (BDh) was measured within 5 minutes after defla-
tion of a blood pressure cuff. Another baseline brachial artery 
diameter (BD1) was measured after 20 minutes of rest after 
reactive hyperemia. Vasodilator response was obtained (BDn) 
within 4 minutes after administration of a single high dose 
(400 mg) of sublingual nitroglycerin tablet. 
EDD was calculated according to the following formula:   
(BDh-BD0) 
× 100 (%) BD0
EID was calculated according to the following formula:   
(BDn-BD1) 
× 100 (%) BD1
Statistical analysis
We used a commercial program, SPSS version 17.0 (SPSS 
Inc., Chicago, Illinois, USA) for Microsoft Windows, for sta-
tistical analysis. Numeric variables are expressed as mean ± 
SD. The difference of continuous variables between two groups 
was analyzed using a nonparametric test (Mann-Whitney U 
test). The difference between the baseline and follow-up data 
was analyzed using the paired sample t-test. 
Intraobserver and interobserver agreements in FMD were 
tested using the baseline values of 10 participants according to 
the statistical methods proposed by Bland and Altman.9) All 
measurements were transformed to an equivalent percentage 
scale of agreement, according to the following formula;
Agreement index = 100 - |X1st - X2nd|
                                    (X1st + X2nd)/2 
in which X1st and X2nd are measures obtained in twice-re-
peated evaluation using same technique in the same patient. 
The measure of reproducibility was 2 SD of the intraobserver 
and interobserver agreement indexes. Therefore, these coefficient 
of variations (COV) were equal to 2 SD of     |X1st - X2nd|
                                                                (X1st + X2nd)/2. 
The intraobserver agreement was 90.8% and the COV was 
8.9%. The interobserver agreement was 82.8% and the COV 
was 14.3%. A p value less than 0.05 was considered statistical-
ly significant.
Results
There was no significant difference in the clinical character-
istics including age, body mass index, blood pressure, serum 
cholesterol profile, high sensitive C-reactive protein, and serum 
glucose level between two groups (Table 1). There was no sig-
nificant side-effect associated with use of oral cilostazol except 
headache. Though majority subjects with headache were well 
controlled with oral analgesics, two of 20 smokers dropped 
out because of uncontrolled severe headache. Cilostazol on Endothelial Dysfunction in Smokers | Kyu Seop Kim, et al.
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Baseline EDD was significantly higher in the control group 
than in the smoker group (12.0 ± 4.5 in the control group vs. 
8.0 ± 2.1% in the smoker group, p = 0.002, Fig. 1A). Baseline 
EID was similar in two groups (13.6 ± 4.5% in the control 
group vs. 11.9 ± 4.9% in the smoker group, p = 0.681, Fig. 
1B). After two weeks of oral cilostazol treatment, follow-up 
EDD values were significantly increased in both groups (con-
trol group: 12.0 ± 4.5 to 16.1 ± 3.7%, p = 0.041, Fig. 2A; 
smoker group: 8.0 ± 2.1 to 12.2 ± 5.1%, p = 0.003, Fig. 2B). 
Follow-up EDD in the control group showed higher value 
than that of control group (16.1 ± 3.7 in the control group vs. 
12.2 ± 5.1% in the smoker group, p = 0.018). 
However, follow up EID value was not significantly increased 
compared with baseline value in both groups. (13.6 ± 4.5% to 
16.1 ± 3.7%, p = 0.182 in the control group, Fig. 3A; 11.9 ± 
4.9% to 13.7 ± 4.3%, p = 0.430 in the smoker group, Fig. 3B).
Discussion
In this FMD study with oral cilostazol, we demonstrated 
decreased baseline EDD level in the smoker group and signifi-
cant improvement of EDD with administration of oral cilo-
stazol in this group. However, cilostazol did not change the 
EID in this group.
Nitric oxide (NO), also known as the endothelium-derived 
Table 1. Baseline clinical and laboratory characteristics
Characteristics Non-smokers (n = 10) Smokers (n = 20) p-value
Age (year) 28.0 ± 1.1 29.1 ± 1.9 0.138
Body mass index (kg/m
2)  22.5 ± 2.4 24.0 ± 2.7 0.183
Systolic BP (mmHg) 119.6 ± 9.3 124.6 ± 12.1 0.340
Diastolic BP (mmHg) 70.8 ± 8.8 71.4 ± 5.7 0.909
Total cholesterol (mg/dL)    148 ± 21.7 163.2 ± 29.0 0.190
HDL-cholesterol (mg/dL) 46.4 ± 6.3 47.0 ± 5.7 0.853
Fasting plasma glucose (mg/dL)    85.1 ± 13.2   89.9 ± 11.8 0.143
hs-CRP (mg/L)   2.14 ± 1.02   1.51 ± 0.38 0.165
BP: blood pressure, HDL-cholesterol: high density lipoprotein-cholesterol, hs-CRP: high sensitive C-reactive protein
Fig. 1. Comparison of endothelium-dependent dilatation (EDD) (A) and endothelium-independent dilatation (EID) (B) in the control and smoker group. 
Data are expressed as the mean ± standard deviation.
Fig. 2. Effect of cilostazol treatment on endothelium-dependent dilatation (EDD) in the control group (A) and smoker group (B). A significant effect of 
cilostazol treatment on EDD is observed.
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relaxing factor (EDRF), is a chemical compound which is an 
important signaling molecule in the mammalian bodies. It is 
biosynthesized endogenously from L-arginine and oxygen by 
various nitric oxide synthase (NOS).10) It contributes to vessel 
homeostasis by inhibiting platelet aggregation, vascular smooth 
muscle contraction and growth, and leukocyte adhesion to the 
endothelium.10) FMD is one of methods to exam endothelial 
function. Increased shear stress in the arterial wall, usually caused 
by occlusion of the artery, can open specialized ion channels in 
the endothelium and influxed calcium ions through these chan-
nels stimulate endothelial nitric oxide synthase (eNOS). In-
creased eNOS activity enhanced NO synthesis and elevated 
NO evokes vasodilation.3) The vasodilatory effect of NO, 
EDRF, on the vessel (vasodilation) can be assessed by FMD. 
Arterial distensibility after reactive hyperemia is influenced by 
variable factors. FMD can be influenced by a single high-fat 
meal,11) mental stress,12) cigarette smoking,13) hyperglycemia,14) 
and changes in electrolytes (sodium and calcium).15) Also, EDD 
can be decreased by theophylline (adrenoreceptor agonist) or 
ibuprofen (prostaglandin synthesis inhibitor).16) 
Cigarette smoking is one of the well-known risk factors caus-
ing endothelial dysfunction and there are strong relationships 
between cigarette smoking, atherosclerotic burden, and isch-
emic heart disease.17-19) Cigarette smoking induces initial ath-
erosclerosis and promotes cardiovascular disease through mul-
tiple mechanisms including vasomotor, neurohormonal, and 
hemoatologic dysfunction, and increased oxidative stress19)20) 
Endothelial dysfunction can be resulted from inhaled cigarette 
smoke. Smoking as few as 2 cigarettes a day doubles the num-
ber of damaged endothelial cells in the blood stream.19-21)
There are several drugs improve endothelial dysfunction in-
cluding angiotensin converting enzyme inhibitors, angiotensin 
receptor blockers, and nifedipine in the hypertensive patients, 
statins, fibrates and omega-3 fatty acid in the dyslipidemic pa-
tients, metformin and rosiglitazone in the diabetic patients.22) 
Few studies have been reported in the improvement of endo-
thelial dysfunction in the smokers. Smoking cessation is one of 
the well-known methods to restore endothelial dysfunction.23) 
Guthikonda et al.24) published their study that allopurinol re-
verses endothelial dysfunction in the heavy smokers. Oida et 
al.25) presented that oral cilostazol treatment can be associated 
with improvement of endothelial dysfunction.
Cilostazol, a selective PDE-3 inhibitor, increases cyclic ade-
nosine mono-phosphate (cAMP) in the platelets and inhibits 
platelet aggregation. Moreover, increased cAMP in the vascu-
lar smooth muscle cells activates protein kinase A and decreas-
es intracellular calcium concentration. These effects result in 
vasodilation.26) Yasuda et al.26) reported that two weeks treat-
ment of oral cilostazol increased tissue blood flow through the 
pedal vessels through vasodilation in the patients with periph-
eral arterial occlusive disease. Cilostazol has been approved by 
the Food and Drug Administration (FDA) in the treatment of 
peripheral arterial occlusive disease since 1999.27) Recently, 
triple combination antiplatelet therapy, aspirin, clopidogrel 
and cilostazol, has been reported to reduce thrombotic com-
plication and recurrence of restenosis after implantation of cor-
onary stent, especially in the diabetic patients.28)
Additional effects of cilostazol on the vascular endothelium 
have been described. Cilostazol has been associated with in-
creased NO production. Ikeda et al.29) published their study 
showing cilostazol increased NO production in cultured vas-
cular smooth muscle cells via cAMP pathway. Nakamura et 
al.30) reported that cilostazol dilated thoracic aorta via released 
NO from aortic endothelium. Increased NO production with 
cilostazol treatment can be associated with increased EDD in 
our study. Our result is similar to that of the previously re-
ported article by Oida et al.25) However, the mean age of the 
participants was younger (late twenties vs. late thirties) and 
treated dosage was higher (200 mg per day vs. 150 mg per 
day) in our study. Because of younger age and shorter duration 
of smoking, the EDD level in our study may be associated 
with higher value than that of study by Oida et al.25) 
Cilostazol improved reactive hyperemia in these eighteen 
smokers. This effect can be resulted from the NO production 
and relaxation of smooth muscle cells in the vessel. Endothelial 
dysfunction can be resulted from smoking as a result of in-
Fig. 3. Effect of cilostazol treatment on endothelium-independent dilatation (EID) in the control group (A) and smoker group (B). There is no significant 
difference between baseline and post-treatment values. Also, there is no statistical significance between post EID values of two groups.
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creased oxidative stresses such as oxygen free radical which dis-
turb normal endothelial functions. Therefore, cilostazol can 
improve endothelial dysfunctions caused by cigarette smoking. 
In this study, most of participants complained headache af-
ter cilostazol medication. Most normal participants com-
plained severe headache despite of oral analgesic treatment. 
Moreover, two of 20 smokers dropped out due to severe head-
ache. 
In conclusion, the administration of cilostazol improves the 
vasodilatory response to reactive hyperemia in the smokers. 
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